

**Anti-Antithrombin III (human, native)****Mouse monoclonal antibody, biotinylated**

Subclass: IgG1/k

PRODUCT NO.

**HYB 230-01 B**

Clone: 1 B7

---

SPECIFICITY	HYB 230-01 is specific for human Antithrombin III (AT III) native form
IMMUNOGEN	Antithrombin III isolated from human plasma
TESTED APPLICATIONS	ELISA
SPECIES REACTIVITY (POSITIVE)	Human
SPECIES REACTIVITY (NEGATIVE)	Not determined
EPITOPE SPECIFICITY	Not determined

---

## PRESENTATION

Content:	100 µL, 1 mg/mL
Preparation:	Biotinylated
Form:	Liquid
Solvent:	0.01 M phosphate buffer, pH 7.4, with 0.14 M NaCl and 15 mM sodium azide
Storage:	4-8°C without exposure to light. No precautions necessary during handling.

---

## APPLICATION

**ELISA:** HYB 230-01 reacts strongly with native AT III. Strong reaction is seen in ELISA with native AT III coated directly onto the microtiter well. In a sandwich ELISA setup, HYB 230-01B acts as a detection antibody in combination with ABS 014-22 as capture antibody to measure Thrombin-Antithrombin (TAT) complexes.

## TARGET

AT III is a single chain glycoprotein of molecular mass 58 kDa with four glycosylation sites and three intra-molecular disulfide bonds. AT III is normally present in human plasma at a concentration of approx. 12.5 mg/dl. It is the major inhibitor of thrombin. Inactivation of thrombin by AT-III occurs by formation of a covalent bond resulting in an inactive 1:1 stoichiometric complex between the two components.

## REFERENCES

## CONDITIONS

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.